JPH09508265A - 平滑筋細胞におけるｃｄ４４発現 - Google Patents

平滑筋細胞におけるｃｄ４４発現

Info

Publication number
JPH09508265A
JPH09508265A JP7519223A JP51922395A JPH09508265A JP H09508265 A JPH09508265 A JP H09508265A JP 7519223 A JP7519223 A JP 7519223A JP 51922395 A JP51922395 A JP 51922395A JP H09508265 A JPH09508265 A JP H09508265A
Authority
JP
Japan
Prior art keywords
smooth muscle
compound
muscle cells
expression
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP7519223A
Other languages
English (en)
Japanese (ja)
Inventor
クァイ ヒー
エドガー ハーバー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of JPH09508265A publication Critical patent/JPH09508265A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
JP7519223A 1994-01-18 1995-01-18 平滑筋細胞におけるｃｄ４４発現 Pending JPH09508265A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18315694A 1994-01-18 1994-01-18
US08/183,156 1994-01-18
PCT/US1995/000740 WO1995019183A1 (fr) 1994-01-18 1995-01-18 Expression de cd44 dans les cellules des muscles lisses

Publications (1)

Publication Number Publication Date
JPH09508265A true JPH09508265A (ja) 1997-08-26

Family

ID=22671682

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7519223A Pending JPH09508265A (ja) 1994-01-18 1995-01-18 平滑筋細胞におけるｃｄ４４発現

Country Status (5)

Country Link
EP (1) EP0806965A4 (fr)
JP (1) JPH09508265A (fr)
AU (1) AU689226B2 (fr)
CA (1) CA2179391A1 (fr)
WO (1) WO1995019183A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014510101A (ja) * 2011-03-24 2014-04-24 ニューリム ファーマシューティカルズ（１９９１）リミテッド 神経保護ペプチド

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990299A (en) * 1995-08-14 1999-11-23 Icn Pharmaceuticals, Inc. Control of CD44 gene expression for therapeutic use
WO1998006839A1 (fr) * 1996-07-15 1998-02-19 Human Genome Sciences, Inc. Proteine de type cd44
CN112673983A (zh) * 2020-12-21 2021-04-20 重庆工商大学 一种基于糖基化改性大豆分离蛋白的宠物咬胶的制备方法及产品

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007505A1 (fr) * 1991-07-03 1994-04-14 Norpharmco Inc. Utilisation de l'acide hyaluronique sous differentes formes contre la recidive de la stenose arterielle

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014510101A (ja) * 2011-03-24 2014-04-24 ニューリム ファーマシューティカルズ（１９９１）リミテッド 神経保護ペプチド

Also Published As

Publication number Publication date
AU1832695A (en) 1995-08-01
EP0806965A4 (fr) 2000-06-07
AU689226B2 (en) 1998-03-26
CA2179391A1 (fr) 1995-07-20
EP0806965A1 (fr) 1997-11-19
WO1995019183A1 (fr) 1995-07-20

Similar Documents

Publication Publication Date Title
KR101514463B1 (ko) 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
Tedesco et al. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity
Border et al. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1
Jain et al. Role of CD44 in the reaction of vascular smooth muscle cells to arterial wall injury.
Lalani et al. Expression of the gene coding for a human mucin in mouse mammary tumor cells can affect their tumorigenicity
Yotsumoto et al. Expression of adrenomedullin, a hypotensive peptide, in the trophoblast giant cells at the embryo implantation site in mouse
US20090012020A1 (en) Inhibiting formation of atherosclerotic lesions
Ajjan et al. New understanding of the role of cytokines in the pathogenesis of Graves’ ophthalmopathy
CN119074926B (zh) 一种靶向fap的car-t细胞在制备治疗心肌炎慢性期心脏纤维化的药物中的应用
HU215778B (hu) Eljárás szindekántartalom kimutatására biológiai anyagokban, így szövetekben és testnedvekben, a sejtek rosszindulatú transzformációinak jelzésére
JP4489012B2 (ja) 老化細胞由来ｄｎａ合成阻害因子
AU2007308716B2 (en) Inhibition of SOX9 function fn the treatment of proteogl ycan-associated pathophysiological conditions
JPH09508265A (ja) 平滑筋細胞におけるｃｄ４４発現
CN113372435A (zh) 一种促进血管新生的多肽及其制药用途
EP1723970A1 (fr) Composition medicale contenant un inhibiteur medical cxcr3
CA2264570C (fr) Agents inducteurs d'invasion et inhibiteurs d'invasion s'utilisant dans la guerison de plaies et le traitement du cancer
JPH07501524A (ja) ｕＰＡ−Ｒの検出・分離方法及びｕＰＡのｕＰＡ−Ｒへの結合阻止方法
WO2000024869A9 (fr) Methodes de modulation de fusion cellulaire
JP3715313B2 (ja) ヒト細胞接着性タンパク質ａａｍｐ‐１及びその利用
AU2005201289B2 (en) Inhibiting formation of atherosclerotic lesions
US20100291089A1 (en) Ligand of regulating immune response, and use thereof in treating an immune response-related disease
EP1625218A2 (fr) Peptides derives d'heparanase pour la vaccination de patients ateints de tumeurs
WO2007064634A2 (fr) Enterostatine utile comme inhibiteur de l'angiogenese